Sep 22 2023, 08:20
IPCA Laboratories:likely to Top:
This pharma stock is likely to top Rs 1000 levels in 1-2 months
In the last 18 years, only 1.9 % trading se, a part of the pharma industry, has rallied over 20% to hit a fresh 52-week high in September.
The stock rose from Rs 731 on 20 June to Rs 913 recorded on 20 September, which translates into an upside of 24% in 3 months. It hit a fresh 52-week high of Rs 954 on 18 September but witnessed some profit-taking thereafter, largely in line with the trend seen in broader markets.
The stock seems to have formed a strong base above Rs 650 levels. It hit a 52-week low of Rs 670 on 22 May from where it bounced back sharply.
In terms of price action, the stock is trading well above most of the crucial short- and long-term moving averages such as 5,10,30,50,100 and 200-DMA on the daily charts.
The daily Relative Strength Index (RSI) is at 59.4. RSI below 30 is oversold and above 70 is considered overbought, Trendlyne data showed.
“IPCA Laboratories stock has been trading under pressure for the last two years and a few weeks ago, the stock hit its 52-week low of Rs 669.80 as well in the month of May 2023,” Shitij Gandhi, Senior Technical Analyst, SMC Global Securities, said.
Therefore, one can buy the stock from current levels, for the upside target of Rs 1080 levels in the next 5-7 weeks, with a stop loss below Rs 830 levels on a closing basis,” he recommended.
source:et
Sep 22 2023, 08:20